Genprex

© 2024 © 2020 Genprex Inc. All Rights Reserved.

Tagged: Stock Offering

Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering

January 28, 2020

Capital raise follows recent Fast Track Designation by the FDA for Company’s Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso®

Read More